ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb has secured an option to acquire Galecto Biotech, a Copenhagen-based firm developing small molecules targeting proteins implicated in fibrosis. Galecto’s lead compound, TD139, an inhaled galectin-3 inhibitor, is in Phase I studies to treat idiopathic pulmonary fibrosis, a chronic lung disease. BMS must exercise its option within 60 days of completion of a Phase Ib study of TD139. Galecto investors could potentially reap up to $444 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X